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ARTICLE
A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-
Pharmacodynamic Model of Tenofovir for HIV Prevention
Priya Jayachandran1,*, Maria Garcia-Cremades1, Katarina Vučićević1,2, Namandjé N. Bumpus3, Peter Anton4, Craig Hendrix3 and 
Radojka Savić1
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prophylaxis product devel-
opment for sexual transmission of HIV-1. Pharmacokinetic (PK) data from study RMP-02/MTN-006 comparing single dose oral 
tenofovir disoproxil fumarate with single and multiple dose rectal tenofovir (TFV) gel administration in HIV-1 seronegative 
adults was used to construct a multicompartment plasma-rectal tissue population PK model for TFV and tenofovir-diphos-
phate (TFVdp) in plasma and rectal tissue. PK data were collected in five matrices: TFV (plasma, rectal tissue homogenate), 
TFVdp (peripheral blood mononuclear cells, rectal mononuclear cells (MMCs), rectal tissue homogenate). A viral growth com-
partment and a delayed effect compartment for p24 antigen expression measured from an ex vivo explant assay described 
HIV-1 infection and replication. Using a linear PK/pharmacodynamic model, MMC TFVdp levels over 9,000 fmol/million cells 
in the explant assay provided apparent viral replication suppression down to 1%. Parameters were estimated using NONMEM 
version 7.4.
Recent therapeutic advances have revolutionized how HIV-1 
is treated and prevented. Adherence to antiretroviral treat-
ment regimens typically leads to normal life expectancy, and 
adherence to pre-exposure prophylaxis (PrEP) regimens 
results in low rates of new infection.1–5 Tenofovir (TFV) prod-
rugs are recommended as part of combination antiretroviral 
treatment regimens and are proven effective for prophylaxis 
with emtricitabine.6–12 TFV disoproxil fumarate (TDF), a prod-
rug, is hydrolyzed to TFV and subsequently phosphorylated 
intracellularly to TFV diphosphate (TFVdp).13 TFVdp is the 
active form of this nucleoside reverse transcriptase inhibitor 
that leads to virally encoded DNA chain termination.13
PrEP is recommended for individuals at high risk for 
becoming infected with HIV-1.14 In the randomized clini-
cal trials demonstrating oral PrEP efficacy (iPrEx, Partners 
Prep, TDF2, Bangkok Tenofovir Study), there is an increased 
relative risk reduction when outcomes are adjusted for ad-
herence using objective pharmacologic measures (e.g., 
plasma TFV concentrations).7,9–11 Given the challenges of 
adhering to daily oral PrEP indicated by poor adherence in 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✔  Ex vivo explant assays provide a dynamic and quanti-
tative measurement of the cumulative p24 antigen ex-
pression level following HIV-1 infection over an assay time 
period. They have been used in a descriptive and non-
mechanistic way to characterize HIV-1 infection 
dynamics.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  With consideration for viral dynamics and drug degra-
dation over time, what is the intracellular tenofovir-diphos-
phate (TFVdp) concentration in rectal tissue that is needed 
to suppress HIV-1 infection as measured by an ex vivo 
explant challenge?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The pharmacokinetic (PK)/pharmacodynamic model 
provides a novel mechanistic link between tissue TFVdp 
PK and virus kinetics by way of p24 antigen expression 
levels over time. A target intracellular drug concentration 
that provides apparent suppression of viral replication 
down to 1% for a rectal pre-exposure prophylaxis (PrEP) 
microbicide is estimated.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  It will inform the rational design and development of 
novel topical PrEP formulations by providing a quantita-
tive framework to relate site-specific drug concentrations 
to HIV-1 infection suppression.
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some studies, alternative formulations are in development, 
including long-term strategies to minimize the need for 
strong adherence, and “on-demand” approaches that only 
require adherence during periods of sexual risk.15 These al-
ternative systemic and topical formulations (e.g., intravaginal 
ring and vaginal gel) may help overcome barriers associated 
with oral PrEP and provide a greater breadth of formulations 
to choose from.
For PrEP candidates, the target drug exposure necessary 
to prevent HIV-1 infection in plasma, peripheral blood mono-
nuclear cells (PBMCs), and mucosal mononuclear cells 
(MMCs) remains unclear.16 Further, target concentrations 
may differ by exposure route (e.g., oral or rectal).16 Through 
developing pharmacokinetic/pharmacodynamic (PK/PD) 
models to better understand the relationship between drug 
exposure and infection suppression after systemic and 
topical administration, we hope to inform how specific ad-
ministration routes may be tailored to achieve protective 
concentrations at key sites of action.
To explore this PK/PD relationship for topical PrEP, several 
studies have investigated TFV formulated as a microbicide 
gel applied vaginally or rectally.8,17,18 Study RMP-02/MTN-
006 evaluated the PK of TFV 1% vaginal gel applied rectally 
compared with oral 300  mg TDF in HIV-1 seronegative 
adults.18 More significant accumulation of TFVdp than TFV 
occurred in rectal tissue likely due to the longer (60 hours) 
intracellular half-life of TFVdp compared with the shorter 
(31 hours) tissue TFV half-life.19,20 Excised rectal tissue was 
challenged ex vivo with HIV-1, and the extent to which HIV-1 
growth was suppressed in these infected tissue explants, 
denoted by a decline in p24 antigen expression, was used 
as a biomarker for microbicide efficacy.21 The p24 is an 
HIV-1 capsid protein that is detectable in the serum in the 
early stages of infection before the HIV-1 antibody is de-
tected.22 TFVdp was more predictive of ex vivo HIV-1 growth 
inhibition than TFV.21 A logistic regression statistical model 
revealed a decline in cumulative p24 antigen expression that 
was nonsignificant following single dosing of either the oral 
or rectal formulation, but significant following multiple rectal 
dosing due to higher concentrations achieved intracellularly 
with multiple dosing.21 Effective concentration (EC)50,90,95 
levels were predicted as an efficacy end point for ex vivo 
infection suppression, but disease progression over time 
(reflected by the p24 antigen expression-time profile) with 
consideration for p24 variability was not characterized.
We developed a mechanistic in vivo/ex vivo population 
PK/PD model to characterize the baseline viral growth, 
viral growth-response of TFV in ex vivo explant tissue, and 
p24 variability. The model was used to propose in vivo tis-
sue-specific protective levels of TFVdp that may prevent 
HIV-1 infection in the explant challenge. Our findings provide 
a quantitative and mechanistic framework for understand-
ing the PK/PD relationship central to topical PrEP drug 
development, and may be used to inform future product de-
velopment (e.g., rectal enema).
METHODS
Study population design
The full study design of RMP-02/MTN-006 is published 
elsewhere (NCT00984971).18,19,21 The trial was approved 
by the institutional review board at each site (University of 
California at Los Angeles, Los Angeles, CA and Magee-
Women’s Research Institute, Pittsburgh, PA). In brief, it is 
a two-site, phase I, partially blinded, placebo-controlled 
safety, acceptability, and PK trial of TFV 1% vaginal gel 
(44 mg TFV) applied rectally compared with oral 300 mg 
TDF (136 mg TFV) in HIV-1 seronegative adults.18,19 Eighteen 
healthy volunteers received a single dose of oral TDF (arm 
1, single oral). A month later, subjects were randomized 
(2:1) to receive either a single rectal dose of TFV 1% or hy-
droxyethylcellulose (placebo) gel (arm 2, single rectal). A 
month after arm 2 concluded, subjects received 7 consec-
utive doses (home, 6; clinic, 1) of either gel (arm 3, multiple 
rectal).18 Figure 1 illustrates the study design.
Pharmacokinetic sampling
Plasma samples were collected from all individuals 
throughout each arm of the study from 30 minutes through 
14  days after each single exposure and from 30  minutes 
through 24  hours following 7-day rectal exposure.19 TFV 
Figure 1 Schematic of RMP-02/MTN-006 clinical study. Collection times following oral tablet and rectal gel administration per study 
arm for (1) parent and metabolite drug concentration in plasma and rectal matrices and (2) p24 antigen level from HIV-1 infectibility 
study. TDF, tenofovir disoproxil fumarate; TFV, tenofovir; TFVdp, tenofovir-diphosphate.
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concentrations in two compartments (plasma and rectal 
tissue homogenate) and TFVdp in three compartments 
(PBMCs, rectal tissue homogenate, and MMCs) were quan-
tified.21 Rectal tissue biopsies were collected postdose 
in the single exposure arms on days 1 and 7 or 4 and 10 
depending on the randomization group and multiple rectal 
arm at 30 minutes. Compartment concentrations and ex-
plant tissue samples were collected simultaneously at visits 
2 (baseline), 3, 5, 6, 7, 9, 10, and 12.21 Figure 1 illustrates 
the collection times for parent and metabolite compartment 
concentrations measured per matrix and the HIV-1 infect-
ibility study at each visit.
General structural model development
A population approach was used to build the mechanis-
tic PK/PD model (Figure 2) linking a multicompartment PK 
model for plasma with biophase effect compartments for 
each matrix (in vivo) to a viral growth compartment with a 
delayed compartment for p24 antigen expression (ex vivo). 
Modeling was performed with NONMEM (version 7.4; ICON 
PLC, Dublin, Ireland). Data were fitted using the first-or-
der conditional estimation method with interaction except 
when handling data below the lower limit of quantification 
(LLOQ) of the assay (below limit of quantification (BLQ)). 
Diagnostic plots (goodness-of-fit and individual prediction) 
and objective function value (OFV) changes were used to 
evaluate each model iteration. Visual predictive checks 
(VPCs) using 500 simulated datasets were performed to 
assess model appropriateness and suggest improvements. 
Perl-speaks-NONMEM (PsN, version 4.7, 4.8), Pirana (ver-
sion 2.9.7), R (version 3.5.1), and Xpose4 (version 4.6.1) 
were used for data management, model development, and 
data visualization.23
Population pharmacokinetic model development
Plasma matrix. Plasma concentrations following oral 
and rectal administration were modeled separately, then 
jointly. A one-compartment and two-compartment model 
with oral absorption were fitted to the data with and 
without a lag parameter. A rectal absorption rate constant 
and bioavailability (relative to the oral route) were added. 
Initial estimates were based on values obtained from a 
noncompartmental analysis.19 Interindividual variability 
(IIV, η) was added to each PK parameter and assessed for 
model stability and convergence; IIV for ka
oral and V2/F was 
retained. A proportional (oral) and combined additive and 
proportional (rectal) error model described the residual 
variability.
Tissue and cellular matrices. To the plasma PK model, 
tissue and cellular matrices were added using a biophase 
effect compartment approach24:
Figure 2 Schematic of mechanistic population pharmacokinetic/pharmacodynamic (PK/PD) model. (Left, in vivo) Multicompartment 
PK model with a plasma compartment and effect compartments for each cellular (PBMC and MMC) and tissue (rectal tissue 
homogenate) matrix. (Right, ex vivo) Mechanistic PK/PD model with a viral growth compartment and a delayed compartment for 
p24 antigen expression. TFV conversion to TFVdp occurs in MMCs resulting in inhibition of HIV-1 growth and reduction of p24 
antigen expression intracellularly following ex vivo infection with HIV-1. CL, clearance; ka, drug absorption rate constant; kd, death 
rate; kg, growth rate; ko, uptake rate following oral administration; kp, p24 antigen expression rate; kr, uptake rate following rectal 
administration; m, metabolite; MMC, rectal mononuclear cell; P, plasma; PBMC, peripheral blood mononuclear cell; pink, plasma 
PK compartments; Ro, ratio following oral administration; Rr, ratio following rectal administration; TFV, tenofovir; TFVdp, tenofovir-
diphosphate; V2, central volume; V3, peripheral volume; yellow, rectal PK compartments.
182
CPT: Pharmacometrics & Systems Pharmacology
Mechanistic PKPD Model of Tenofovir for HIV Prevention
Jayachandran et al.
where kP-tissue/cellular matrix is the rate of drug entry into the tis-
sue or cellular matrix from the plasma and RP-tissue/cellular matrix 
is a concentration ratio between the tissue or cellular ma-
trix and plasma. The final plasma PK parameter estimates 
were fixed, whereas the rate and ratio of TFV distribution 
into rectal tissue and TFVdp distribution into rectal tissue, 
MMCs, and PBMCs were estimated. Initial estimates were 
based on the raw data. Both rate and ratio terms were strat-
ified by administration route (oral: ko_plasma-tissue/cellular matrix, 
Ro_plasma-tissue/cellular matrix; rectal: kr_plasma-tissue/cellular matrix, 
Rr_plasma-tissue/cellular matrix), and reported in their original units. 
For PBMCs, a rectal rate and ratio term was not estimated 
because the concentrations in the single and multiple rectal 
arms were BLQ. Due to data sparsity in the tissue matrices, 
a sensitivity analysis was performed on the rate terms to de-
termine if the uptake was either slow or fast. On the basis of 
model stability, convergence, OFV, and VPCs, the rates were 
fixed to either a “low” or “high” value indicating either a slow 
or fast uptake, respectively. IIV was added to the ratio term 
for each tissue and cellular matrix, and a proportional error 
model was used for each tissue or cellular matrix to assess 
the residual variability. For plasma, the LLOQ was 0.3 ng/mL; 
for the tissue and cellular matrices, each sample had its 
own unique LLOQ value based on cell count or biopsy mass 
and drug assay sensitivity per sample. The likelihood that 
observations deemed BLQ were less than the LLOQ (M3) 
was modeled with the Laplacian estimation method (not 
reported).25
Pharmacodynamic sampling
Explant tissue samples were collected at baseline (visit 2) 
and postdose in the single exposure arms on days 1 and 7 
or 4 and 10 depending on the randomization group (visits 
3, 5, 6, 7, 9, and 10) and multiple rectal arm at 30 minutes 
postdose (visit 12).21 These samples were infected ex vivo 
with HIV-1 within 1–2 hours of harvesting.21 Supernatants 
were collected on days 0 or 1, 4, 7, 11, and 14 to quantify 
p24 antigen levels.21 Measurements across 4 biopsies were 
averaged and added to the p24 antigen concentration from 
the previous time point to provide a cumulative level at each 
post-challenge timepoint.
Population PK/PD model development
PK/PD baseline model. Initially, baseline (absence of 
drug) p24 antigen expression characterizing viral replication 
and growth was described using linear, exponential, shifted 
logistic, 3-parameter Gompertz, 4-parameter Weibull, and 
mechanistic structural models. The mechanistic model 
was chosen due to its resemblance to the physiological 
system and was developed from a viral dynamics model.26 
It consists of an exponential HIV-1 viral growth model with 
a death rate and a delayed effect compartment describing 
the rate of p24 antigen expression:
where V is HIV-1 virus (virions/mL), P is p24 antigen level 
(pg/mL), kg is viral growth rate (/hour), kd is viral death 
rate (/hour), kp is p24 antigen expression rate (/hour), E is 
drug treatment effect, and R is ratio of virus to p24 antigen 
level. Assumptions included a negligible immune effect and 
constant kp.
26 Both kd and R were estimated while kg and 
kp were fixed to literature values of 0.045/hour and 0.0059/
hour, respectively.27,28 Residual variability was described by 
a combined additive and proportional error model. IIV was 
added to each rate term; IIV on kp was fixed for modeling 
the treatment effect. Initial conditions were 104 virions for V 
and zero for P.
PK/PD model with drug degradation effect. The PK/PD 
relationship for the MMC matrix was modeled using three 
relationships: linear, maximum effect (Emax), and sigmoid 
Emax. The simplest relationship (linear) that characterized 
the data well was selected based on OFV, diagnostic 
plots, and VPCs. The drug treatment effect was modeled 
as E  =  SL * CP where SL is slope (pg/mL)/(fmol/million 
cells) and CP is MMC TFVdp concentration (fmol/million 
cells). Two modes were explored: inhibition of growth 
(1-E) and acceleration of death (1+E). Similar results were 
obtained for both models; the former was selected based 
on TFV mechanism of action. Explant tissue collected 
30-minutes postdose administration was linked to the 
MMC TFVdp concentrations measured at 30  minutes 
postdose for the exposure-response relationship. The 
drug degradation time course during the explant assay 
was not studied; therefore, a constant rate of 0.0018/hour 
was assumed based on TFV drug degradation kinetic 
tests and modeled with an exponential decay.29 All other 
parameter estimates were fixed to the final estimates from 
the baseline model and SL was estimated. The explant 
assay LLOQ was 10  pg/mL; all BLQ observations were 
modeled using the M5 method.25
Simulations to determine target tenofovir 
concentrations to suppress HIV-1 infection
Using the PK/PD model, simulations were performed using 
the PKPDsim R package (version 1.0.1) to determine the 
target TFVdp concentration in MMCs necessary to achieve 
apparent viral replication suppression down to 1% in the 
explant assay. Viral replication trajectories were simulated 
for 2 weeks over a concentration range of 0 to 11,000 fmol/
million cells; the lower end emulates the expression profile 
in the raw data, whereas the higher end describes the ex-































= kgV (1 − E) − kdV
(6)dP
dt
= kp (RV − P)
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infection. Apparent viral replication suppression down to 
1% was calculated using the linear relationship for drug 
treatment effect, E  =  kg(1-SL*CP). When no drug is pres-
ent, the effect captures the uninhibited growth of the virus. 
Using 1% of the maximum effect, the MMC TFVdp concen-
tration necessary for apparent viral replication suppression 
down to 1% was calculated.
RESULTS
Study population data
Eighteen subjects (14 men and 4 women) aged 22 to 
66 years old provided drug concentration levels in plasma 
(TFV), PBMC (TFVdp), rectal tissue homogenate (TFV and 
TFVdp), and MMC (TFVdp) matrices (Figure 1). After dose 
administration, subjects provided rectal tissue for ex vivo 
HIV-1 infection from which p24 antigen levels were mea-
sured across the explant assay time course. The total 
number of PK samples for each matrix and cumulative 
p24 antigen observations for each study arm are shown in 
Table  S1; measured concentrations that are BLQ are de-
noted as a percentage per matrix.
Population pharmacokinetic model
A multicompartment PK model consisting of 7 compart-
ments (Figure 2) described the TFV and TFVdp PK time 
course in plasma and tissue/cellular matrices (Figure 3). 
The plasma PK was described by a two-compartment 
model with oral absorption. Biophase effect compart-
ments for each tissue and cellular matrix for parent and 
metabolite drug concentrations were added. Table 1 
provides the PK parameter estimates with relative stan-
dard errors per matrix. The model described the data 
well; owing to data sparsity (Table S1) in the tissue and 
PBMC matrices, VPCs for only the key matrices (plasma 
and MMC) stratified by study arm are shown in Figure S1. 
Applying the M3 method to BLQ observations resulted in 
parameter estimates with large relative standard errors 
(not shown) likely due to the large percentage of BLQs in 
the matrices (Table S1).
Population PK/PD model
The cumulative p24 antigen expression time course across 
the explant assay is shown in Figure 4, and further stratified 
by PK percentile for each MMC type in Figure S2. For higher 
TFVdp concentrations, greater expression suppression is 
seen, which is captured by the slope of the colored lines 
(compared with baseline). The cumulative p24 antigen levels 
as a function of drug concentration are similar regardless of 
MMC type, which is expected given the high correlation of 
drug concentrations between each MMC type (Figure S3).
The p24 antigen expression was modeled for CD4
+, CD4
−, 
and total cells using a PK/PD model. The parameter esti-
mates are provided for the baseline model (Table S2) and 
final model (Table 2). The final model described the data well 
and no significant misspecifications were observed from the 
goodness-of-fit plots or the VPCs stratified by study arm 
(Figure S4). Accounting for the decline in drug concentra-
tion across the assay time course, a significant decrease 
in OFV relative to the “PK/PD effect” was observed for the 
“drug degradation effect” model, and the PK/PD effect was 
significant for all cell types (Table S3). Cell separation did 
not affect the assessment of drug efficacy, as evidenced by 
the similar value for the slope term in the drug degradation 
effect model for each cell type.
Target tenofovir concentrations to suppress HIV-1 
infection
Given the high correlation of TFVdp concentration across 
MMC types, the final model for the total cell type was used 
to perform simulations to determine a target MMC TFVdp 
concentration to obtain an apparent suppression of viral 
replication down to 1% in the explant assay (Figure 5). 
The simulated viral growth trajectories at low concentra-
tions (e.g., 500  fmol/million cells) mimic the p24 antigen 
Figure 3 Pharmacokinetic profiles of raw data. Parent and metabolite drug concentration-time profiles stratified by matrices and 
study arm. Concentrations deemed below the limit of quantification are not included. fmol, femtomole; mg, milligram; mL, milliliter; 
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expression profiles of the raw data. At higher concentra-
tions (above 5,500  fmol/million cells), the slope plateaus 
and then trends downward. This change in virus trajectory 
suggests a failure to sustain replication, eventually leading 
to suppression. A target concentration of 9,000 fmol/million 
cells is required for apparent suppression of viral replica-
tion down to 1% for the explant challenge.
DISCUSSION
The pivotal oral PrEP efficacy trials identified the negative im-
pact poor adherence has on HIV-1 prevention. Topical PrEP 
formulations used episodically represent one strategy to 
overcome this hurdle. A development challenge is ensuring 
there is a high enough active drug concentration (TFVdp) for 
a long enough time period within the target cells in the rectal 
mucosa. PK/PD modeling of data from completed oral PrEP 
efficacy trials can guide development of these equally effi-
cacious topical formulations that achieve low systemic drug 
concentrations. Using data from study RMP-02/MTN-006, 
we built a mechanistic in vivo/ex vivo PK/PD model using 
nonlinear mixed effects modeling to quantify a dose-concen-
tration-response relationship and propose a target TFVdp 
concentration in colorectal tissue cells from an explant chal-
lenge. The multicompartment PK model characterizes TFV 
and TFVdp distribution in plasma and at local sites of infec-
tion and drug action with estimates of typical values for key 
PK parameters (CL, V, ka, and F) per administration route 
and with consideration for hierarchies of variability (interindi-
vidual and residual). The in vivo MMC TFVdp concentration 
linked to ex vivo p24 antigen levels captures the basic viral 
dynamics of HIV-1 growth and its suppression by TFV over 
time. The target TFVdp concentration established using an 
explant challenge model holds high value in prevention trials 
where viral challenges cannot be performed.
Several assumptions were used to create the PK/PD 
model. A negligible immune cell effect (given the absence 
of ingress/egress of blood/immune cells) contributing to 
virus death and a constant rate of p24 antigen production 
and viral growth were assumed to reduce the complexity of 
HIV-1 viral dynamics. The model presents the worst-case 
scenario in which any reduction in viral growth is solely due 
Table 1 Pharmacokinetic model parameter estimates




oral (/hour) 1.78 (30) 51.2 (33)
CL/F (L/hour) 52.1 (8) —
Q/F (L/hour) 7.90 (14) —
V2/F (L) 679 (11) 21.2 (31)
V3/F (L) 399 (12) —
ka
rectal (/hour) 22.2 (45) —
Frectal 0.102 (17) —
Proportional error (oral) (%CV) 51.5 (8) —
Proportional error (rectal) (%CV) 52.0 (17) —
Additive error (rectal) (mcg/L) 3.71 (18) —




Ro_P-RT ((ng/mg)/(mcg/L)) 2.05 (19) —
Rr_P-RT ((ng/mg)/(mcg/L)) 171 (95) —
Proportional error (%CV) 100 (14) —




Ro_P-RTm ((fmol/mg)/(mcg/L)) 530 (51) —
Rr_P-RTm ((fmol/mg)/(mcg/L)) 540 (2) —
Proportional error (%CV) 238 (7) —
MMC TFVdp ko_P-MMC (/hour) 0.0102 (13) —
kr_P-MMC (/hour) 0.0606 (71) —
Ro_P-MMC ((fmol/million cells)/(mcg/L)) 11.4 (16) —
Rr_P-MMC ((fmol/million cells)/(mcg/L)) 1530 (24) —
Proportional error (%CV) 133 (12) —
PBMC TFVdp ko_P-PBMC (/hour) 0.0320 (49) —
Ro_P-PBMC ((fmol/million cells)/(mcg/L)) 0.169 (61) —
Proportional error (%CV) 461 (22) —
Final parameter estimates for the multicompartment pharmacokinetic model stratified by matrices and both parent and metabolite drug concentration. 
%CV, percent coefficient of variation; CL/F, total apparent clearance; F, bioavailability; fmol, femtomole; IIV, interindividual variability; ka, absorption rate 
constant; L, liter; m, metabolite; mcg, microgram; mg, milligram; MMC, rectal mononuclear cell; ng, nanogram; o, oral; P, plasma; PBMC, peripheral blood 
mononuclear cell; Q/F, intercompartmental clearance; r, rectal; RSE, relative standard error; RT, rectal tissue; TFV, tenofovir; TFVdp, tenofovir-diphosphate; 
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to the drug effect, not a combination of a drug and immune 
effect. Furthermore, the trajectory of p24 antigen expres-
sion closely matches that of HIV-1 viral load and the levels 
are detectable 10–15 days after infection.28,30 Therefore, a 
delayed effect compartment was assumed to capture p24 
antigen expression after tissue infection (Eq. 6).
Despite lower plasma TFV levels, topical rectal administra-
tion yielded faster absorption into plasma and higher TFVdp 
levels in rectal tissue and MMCs compared with systemic 
oral administration. Rapidly achieving high intracellular TFVdp 
concentrations in target rectal mucosal cells following rectal 
administration results in faster virus suppression with less 
total drug exposure than via the oral route. This suggests 
that topical rectal PrEP may overcome the need to dose oral 
drugs in advance of potential rectal HIV-1 exposure while also 
achieving higher target tissue concentrations when used in an 
“on-demand” regimen. Therefore, collecting rectal tissue in ad-
dition to plasma in phase I studies is critical, and is now done 
routinely. By correlating a tissue with a plasma prophylactic 
concentration using the effect compartment model, the esti-
mate of a preventive plasma concentration, which likely differs 
for oral compared with topical dosing, might be determined.
The multicompartment PK model is data-informed; it does 
not describe intracellular TFV metabolism or the precise di-
rection of drug movement after oral or rectal administration 
because data to support these relationships are unavail-
able. Drug movement is guided by central (plasma) and local 
(capillary) blood systems, and, over time, the concentration 
equilibrates between the plasma and rectal tissues. The effect 
compartment model provides an estimate of a relative ratio 
that describes this drug movement between the plasma and 
tissue/cell while making minimal assumptions. This simple 
model structure is useful to inform the PK given the data spar-
sity and is preferable to prior noncompartmental analyses that 
cannot describe the aforementioned relationships adequately.
Richardson-Harman et al. estimated an explant TFVdp 
EC90 of 1,318, 13,183, and 8,313 fmol/million cells for CD4
−, 
CD4
+, and total MMC cell types, respectively.21 The EC90 for 
total MMCs is close to our proposed target MMC TFVdp 
concentration of 9,000 fmol/million cells estimated from sim-
ulations using the PK/PD model. In the DREAM-01 study 
evaluating the PK of three formulations of TFV enema in men, 
an explant EC50 of 2,000 and EC90 of 20,000 fmol/million cells 
has been reported from preliminary analyses.31 By contrast, 
the PK/PD relationship between PBMC TFVdp concentra-
tion and HIV-1 seroconversion in the iPrEx study provided 
a clinical IC90 of 40 fmol/M PBMC (95% confidence interval: 
8–70) and IC99 of 53 fmol/M PBMC (95% confidence inter-
val: 15–150).32,33 In the HPTN 066 prevention study, which 
used directly observed dosing, these PBMC concentrations 
were consistent with daily TDF dosing and a median colon 
tissue cell TFVdp concentration of 160 fmol/million cells as a 
clinical 90% inhibitory concentration (IC90) correlate for rectal 
mucosa. Taken together, these estimates indicate a > 50-fold 
difference between clinical and explant IC90 estimates.
Some of the apparent difference between the clinical and 
explant IC90 may be explained by limitations of the explant 
challenge study. The assay uses a high inoculum for infection 
and crude sample preparation techniques that are not reflec-
tive of clinical infection through receptive anal intercourse. 
The traumatic removal of rectal tissue using biopsy forceps is 
greater and deeper than coital trauma disruption and exposes 
Figure 4 Pharmacodynamic profiles of raw data. Cumulative p24 antigen expression profiles stratified by [left] drug administration 
compared with baseline (no treatment) and [right] single (single oral, single rectal)/multiple (multiple rectal) drug administrations 
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an unprotected tissue surface that lacks the protective mucus 
and epithelial layers, likely enhancing the infectibility of the bi-
opsy and resulting in the need for higher drug concentrations 
to fully prevent HIV-1 infection. Additionally, isolating the sim-
ulated HIV-1 challenge to a small colon biopsy detached from 
the rest of the body does not address those virions escaping 
mucosa to lymph nodes and the systemic circulation.
The PK/PD model has some limitations. Firstly, the study 
population was limited to 18 subjects. A large percentage 
of the observations were BLQ for tissue and cellular matri-
ces, particularly the PBMC matrix, which may be due to low 
TFVdp exposure in the plasma after rectal dosing. The PK 
collection times in the trial were identical for oral and rectal 
administration; however, the rectal formulation had a lower 
dose (44 mg) and bioavailability (~ 10%) compared with the 
oral formulation. Therefore, the trial design was predisposed 
for a higher percentage of BLQs following rectal administra-
tion. Additionally, the cumulative p24 antigen levels were linked 
to MMC TFVdp concentrations at a single time point (30 min-
utes postdose corresponding to the time of explant infectivity). 
Lastly, during the 14-day assay, the tissue cells’ ability to sus-
tain viral replication was not measured nor was the time course 
of TFVdp concentration quantified. Future studies should mea-
sure the drug degradation effect on viral growth dynamics and 
replication sustainability to derive unbiased model parameter 
estimates and maximize the utility of the explant assay.
Table 2 PK/PD drug degradation model parameter estimates
Parameter











a 0.00400a 0.00400a 72.5b 72.5b 72.5b
Ratio [pg/virions] 0.0404b 0.0404b 0.0404b
kdegradation [/hour] 0.0018
a 0.0018a 0.0018a - - -
Slope [(pg/mL)/(fmol/million cells)] 0.00042 (9) 0.00008 (44) 0.00011 (11) 171.2c
Proportional error [%CV] 86.9 (5) 85.7 (6) 87.6 (6) - - -
Additive error [pg/mL] 3.53 (10) 3.60 (10) 3.61 (11) - - -
Parameter estimates for the pharmacokinetic-pharmacodynamic model with drug degradation effect (final model) stratified by MMC type (CD4
-, CD4
+, total).
%CV, percent coefficient of variation; IIV, interindividual variability; MMC, rectal mononuclear cell; PD, pharmacodynamic; PK, pharmacokinetic; RSE, rela-
tive standard error.
aEstimate fixed to literature value.
bEstimate fixed from baseline model.
cEstimate fixed from previous iteration of model (PK/PD model).
Figure 5 Simulated target MMC TFVdp concentration for apparent HIV-1 replication suppression. Simulation of cumulative p24 
antigen expression profiles over the assay time course (14 days) using the total MMC cell type pharmacokinetic-pharmacodynamic 
model with drug degradation effect (final model). Raw p24 antigen expression data are superimposed (black circles). fmol, femtomole; 
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In conclusion, we developed a quantitative framework for 
understanding a central PK/PD relationship in topical PrEP 
product development, and we identified a target ex vivo 
tissue-specific prophylactic TFVdp concentration. The ap-
proach may be applied to future PrEP product studies that 
correlate ex vivo tissue infectibility with plasma and tissue 
drug concentration after in vivo application of a systemic 
or topical product for any cellular/tissue compartment for 
which PK data are collected irrespective of the exposure 
route. Future directions include studying the relationship 
between ex vivo and in vivo target intracellular prophylactic 
concentrations using PrEP clinical trial data to further re-
align data from ex vivo explant assays with effective in vivo 
target TFVdp concentrations. This re-alignment provides a 
target ex vivo tissue-specific prophylactic concentration that 
may be translatable to an in vivo target TFV concentration 
to guide dose selection. Topical PrEP product development 
better informed by these PK/PD models improves the pos-
sibility of providing another prophylaxis option for high-risk 
populations that prefer an alternative formulation to a daily 
oral pill.
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